-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Raised to $815 at Guggenheim
-
-
-
-
-
-
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
-
-
-
-
-
-
Sanofi (SNY) and Regeneron (REGN) Announce FDA to review sBLA for Praluent Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
-
-
-
-
-
-
-
FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
-
-
-
-
-
-
-
UPDATE: UPDATE: Piper Jaffray Upgrades Regeneron (REGN) to Overweight
-
-
-
-
-
-
-
Regeneron (REGN), Sanofi (SNY) Announce EMA Acceptance of Dupixent Marketing App
-
-
-
-
-
-
-
Roth Capital Reaffirms Regeneron (REGN) at 'Buy'; Dupilumab BLA in AD Key Next Step in Development
-
15,434 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

